Biotech

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of MyoKardia, Inc.   breached their fiduciary duties in connection with the proposed sale of the Company to Bristol Myers Squibb . On October 5, 2020 MyoKardia announced that it had entered into a definitive merger agreement with Bristol Myers Squibb. Under the terms of the merger agreement, a subsidiary of ...

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of MyoKardia, Inc. ("MyoKardia" or the "Company") (NASDAQ: MYOK) breached their fiduciary duties in connection with the proposed sale of the Company to Bristol Myers Squibb (NYSE: BMY).

On October 5, 2020 , MyoKardia announced that it had entered into a definitive merger agreement with Bristol Myers Squibb. Under the terms of the merger agreement, a subsidiary of Bristol Myers Squibb will acquire all of the outstanding shares of MyoKardia's common stock for $225.00 per share in cash.

The investigation concerns whether the MyoKardia board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for MyoKardia shares of common stock.

If you are a shareholder of MyoKardia and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker ( jimb@johnsonfistel.com ) at 619-814-4471 . If emailing, please include a phone number.

Additionally, you can [ Click here to join this action ]. There is no cost or obligation to you.

About Johnson Fistel , LLP:
Johnson Fistel , LLP is a nationally recognized shareholder rights law firm with offices in California , New York , and Georgia . The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com . Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel , LLP
Jim Baker , 619-814-4471
jimb@johnsonfistel.com

[ Click here to join this action ]

Cision View original content: http://www.prnewswire.com/news-releases/myok-alert-johnson-fistel-investigates-proposed-sale-of-myokardia-is-225-a-fair-price-301145607.html

SOURCE Johnson Fistel , LLP

News Provided by PR Newswire via QuoteMedia

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECHTM-processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other disease states beyond hypertension where it has already shown tremendous promise

Keep reading... Show less
Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

(TheNewswire)

Lexaria Bioscience Corp.

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Keep reading... Show less
BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

  • Cannabis produced has a Trichomes density of up to 200 times greater than in a plant-grown product while solving major industry challenges of consistency, safety, and environmental sustainability
  • The Company is ready to engage with key players in the global Cannabis industry

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. (For full illustration, watch the "Cannabis Without Plants - History in the Making" video at https:youtu.beNAurl6oa1xo)

Keep reading... Show less
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/.

Keep reading... Show less

Amgen Announces New Data Being Presented At ASH 2021

- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 .

"The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers," said David M. Reese , M.D., executive vice president of Research and Development at Amgen. "By accelerating the development and delivery of transformative medicines in difficult to treat and vulnerable patient populations, including children and pregnant women, we continue to focus on the relentless pursuit of breakthroughs for blood cancer patients and their families."

Keep reading... Show less

Upadacitinib Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

ABBVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more biologics. 1 U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. 1

"The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino , M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."

Keep reading... Show less

Top News

Related News